NovoCure (NVCR) Competitors $12.03 +0.12 (+1.01%) Closing price 04:00 PM EasternExtended Trading$11.98 -0.04 (-0.37%) As of 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NVCR vs. IRTC, GKOS, BLCO, TMDX, SLNO, NVST, LIVN, INSP, WRBY, and LQDAShould you be buying NovoCure stock or one of its competitors? The main competitors of NovoCure include iRhythm Technologies (IRTC), Glaukos (GKOS), Bausch + Lomb (BLCO), TransMedics Group (TMDX), Soleno Therapeutics (SLNO), Envista (NVST), LivaNova (LIVN), Inspire Medical Systems (INSP), Warby Parker (WRBY), and Liquidia Technologies (LQDA). These companies are all part of the "medical equipment" industry. NovoCure vs. Its Competitors iRhythm Technologies Glaukos Bausch + Lomb TransMedics Group Soleno Therapeutics Envista LivaNova Inspire Medical Systems Warby Parker Liquidia Technologies iRhythm Technologies (NASDAQ:IRTC) and NovoCure (NASDAQ:NVCR) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation. Is IRTC or NVCR more profitable? iRhythm Technologies has a net margin of -14.06% compared to NovoCure's net margin of -27.13%. NovoCure's return on equity of -47.74% beat iRhythm Technologies' return on equity.Company Net Margins Return on Equity Return on Assets iRhythm Technologies-14.06% -90.03% -8.52% NovoCure -27.13%-47.74%-13.79% Do institutionals and insiders believe in IRTC or NVCR? 84.6% of NovoCure shares are owned by institutional investors. 1.1% of iRhythm Technologies shares are owned by insiders. Comparatively, 5.5% of NovoCure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts rate IRTC or NVCR? iRhythm Technologies currently has a consensus target price of $163.82, indicating a potential downside of 4.46%. NovoCure has a consensus target price of $28.79, indicating a potential upside of 139.28%. Given NovoCure's higher probable upside, analysts clearly believe NovoCure is more favorable than iRhythm Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iRhythm Technologies 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.00NovoCure 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57 Which has higher valuation and earnings, IRTC or NVCR? iRhythm Technologies has higher revenue and earnings than NovoCure. iRhythm Technologies is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioiRhythm Technologies$657.23M8.38-$113.29M-$2.93-58.52NovoCure$605.22M2.22-$168.63M-$1.56-7.71 Does the media refer more to IRTC or NVCR? In the previous week, iRhythm Technologies had 8 more articles in the media than NovoCure. MarketBeat recorded 15 mentions for iRhythm Technologies and 7 mentions for NovoCure. iRhythm Technologies' average media sentiment score of 0.90 beat NovoCure's score of 0.54 indicating that iRhythm Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRhythm Technologies 8 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NovoCure 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, IRTC or NVCR? iRhythm Technologies has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500. Comparatively, NovoCure has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. SummaryiRhythm Technologies beats NovoCure on 11 of the 17 factors compared between the two stocks. Get NovoCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NVCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVCR vs. The Competition Export to ExcelMetricNovoCureMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.34B$3.06B$5.76B$9.84BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-7.7121.1931.3126.63Price / Sales2.22392.62461.66121.17Price / CashN/A44.4437.7659.36Price / Book3.848.0710.026.69Net Income-$168.63M-$54.08M$3.27B$265.59M7 Day Performance1.01%2.32%3.17%3.44%1 Month Performance3.35%3.47%4.36%1.12%1 Year Performance-39.03%18.51%44.16%23.91% NovoCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVCRNovoCure4.1445 of 5 stars$12.03+1.0%$28.79+139.3%-33.8%$1.34B$605.22M-7.711,488IRTCiRhythm Technologies1.317 of 5 stars$165.68-2.0%$162.64-1.8%+149.9%$5.32B$657.23M-56.552,000Analyst ForecastGKOSGlaukos4.7289 of 5 stars$91.78-2.5%$127.42+38.8%-29.5%$5.26B$383.48M-55.62780Analyst RevisionBLCOBausch + Lomb1.1758 of 5 stars$14.57-2.5%$15.56+6.8%-10.2%$5.16B$4.79B-18.6713,500TMDXTransMedics Group2.8974 of 5 stars$114.97-4.1%$123.00+7.0%-33.3%$3.92B$441.54M59.57210Positive NewsAnalyst ForecastSLNOSoleno Therapeutics4.5612 of 5 stars$66.51-3.0%$115.09+73.0%+38.0%$3.53B$32.66M-16.0730News CoverageAnalyst ForecastNVSTEnvista3.5955 of 5 stars$21.15-2.6%$20.92-1.1%+13.6%$3.51B$2.51B66.1012,300Positive NewsLIVNLivaNova1.6164 of 5 stars$56.35+0.8%$59.71+6.0%+21.2%$3.08B$1.25B-14.492,900Positive NewsINSPInspire Medical Systems4.9347 of 5 stars$93.20-2.9%$165.62+77.7%-50.9%$2.84B$861.31M53.881,246Positive NewsWRBYWarby Parker2.1665 of 5 stars$26.18-3.1%$24.06-8.1%+72.7%$2.75B$771.32M-373.883,780LQDALiquidia Technologies3.6052 of 5 stars$26.25-2.2%$32.11+22.3%+190.2%$2.26B$19.32M-15.4450Positive News Related Companies and Tools Related Companies iRhythm Technologies Alternatives Glaukos Alternatives Bausch + Lomb Alternatives TransMedics Group Alternatives Soleno Therapeutics Alternatives Envista Alternatives LivaNova Alternatives Inspire Medical Systems Alternatives Warby Parker Alternatives Liquidia Technologies Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NVCR) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovoCure Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share NovoCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access